Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Anti-CRISPR Proteins Could Improve Accuracy of Gene Editing



According to the researchers – whose work was published in the journal, Science Advances – the anti-CRISPR proteins could stop the gene editing tool from over-editing after the desired changes have been made.

Share this!

July 14, 2017 | by Sarah Hand, M.Sc.

CRISPR gene editing has the potential to be a powerful tool in the fight against genetic disease, however concerns surrounding potential off-target mutations could limit its use. Now, researchers from the University of California (UC) Berkeley and UC San Francisco have shown that newly-identified anti-CRISPR proteins could help improve the accuracy of the gene editing technique.

The CRISPR-Cas9 gene editing tool was originally found in certain strains of bacteria, which would use the enzymes to protect against invading viruses, known as bacteriophages. Over time, those viruses developed anti-CRISPR proteins to counteract the host’s immune system.

The UC researchers found that these viral anti-CRISPR proteins could reduce off-target effects of gene editing by as much as four times less than when the CRISPR tool was used on its own. According to the researchers – whose work was published in the journal, Science Advances – the anti-CRISPR proteins could stop the gene editing tool from over-editing after the desired changes have been made.

“Unexpected mutations can arise as a result of off-target gene editing, but our paper – like many others – shows that off-target effects can be modulated and it is not as serious as people might think,” said first author Jiyung Jenny Shin, a postdoctoral fellow at UC Berkeley.

In particular, an anti-CRISPR protein known as AcrIIA4 was able to reduce the number of off-target mutations by a factor of four in a human cell culture gene editing experiment involving the removal of a mutated hemoglobin gene involved in the development of sickle cell disease. Importantly, AcrIIA4 was able to reduce inappropriate changes to the genome without significantly reducing the desired effect of CRISPR.

“Even after six hours of effective CRISPR, inserting anti-CRISPR decreases off-target effects by more than two-fold compared to on-target effects,” said Shin. “Therapeutically, you could treat a patient with CRISPR first, and then treat with anti-CRISPR at a later time and decrease off-target effects.”

The researchers believe that these anti-CRISPR enzymes could become standard once CRISPR gene editing is used therapeutically in human patients. Last year, researchers at Sichuan University in Chengdu, China were the first to introduce CRISPR-edited cells into a human patient, however human clinical trials of the tool have yet to commence in the US.

“The ability to turn Cas9 gene editing off is just as important as the ability to turn it on,” said Jacob Corn, scientific director for biomedicine of the IGI and a UC Berkeley assistant adjunct professor of molecular and cell biology. “Imagine if you had an electric razor with no off-switch! For eventual therapeutic applications, it is critical to be able to precisely control when and where gene editing is active. The anti-CRISPR proteins offer opportunities to completely turn off Cas9 as well as fine-tune its activity.”

A controversial study published in the journal Nature Methods in May, suggested that CRISPR could introduce hundred, if not thousands, of unintended mutations into the genome. However, a recent article published in Forbes shared the analysis by another group of researchers, who found that the number of off-target mutations attributable to CRISPR in the Nature Methods paper may have been exaggerated.

Keywords:  CRISPR, Gene Editing, Mutations


Share this with your colleagues!

Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News

Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News

Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.